AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.
Last trade$0.7102
Day change+$0.0102 (+1.46%)
Day range$0.6911 – $0.739
Volume573,146
Market cap$52M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$51.75M
Price / earnings
—
Price / book
0.49×
Price / sales
0.35×
EV / sales
0.5×
EV / EBITDA
16.46×
Profitability
Earnings per share
-$0.13
Return on assets
-5.01%
Return on equity
-8.87%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.35×
Current ratio
0.85×
Quick ratio
0.85×
Cash ratio
0.56×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$2.54M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AIRS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$31.94M
$42.9M
$39.39M
$33.44M
$34.99M
$44.01M
$39.37M
$39.18M
Cost of revenue
$12.91M
$16.57M
$15.59M
$13.68M
$14.86M
$17.2M
$15.95M
$16.51M
Gross profit
$19.03M
$26.33M
$23.8M
$19.77M
$20.13M
$26.81M
$23.42M
$22.66M
Selling, general and administrative
$20.26M
$23.42M
$22.58M
$18.22M
$19.53M
$22.67M
$21.77M
$23.36M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$23.17M
$26.36M
$25.6M
$18.62M
$29.88M
$26.03M
$25.01M
$26.56M
Operating income
-$4.14M
-$29K
-$1.8M
$1.15M
-$9.75M
$786K
-$1.59M
-$3.9M
Interest expense
-$1.24M
-$1.04M
-$1.2M
-$1.48M
-$1.41M
-$1.56M
-$1.63M
-$1.61M
Income before taxes
-$5.38M
-$1.21M
-$2.86M
-$2.49M
-$11.16M
-$776K
-$3.21M
-$5.51M
Income taxes
$1.79M
-$101K
-$465K
-$3.77M
-$1.65M
-$185K
-$367K
-$706K
Net income
-$7.17M
-$1.11M
-$2.4M
$1.28M
-$9.51M
-$591K
-$2.85M
-$4.8M
Net income attributable to common shareholders
-$7.17M
-$1.11M
-$2.4M
$1.28M
-$9.51M
-$591K
-$2.85M
-$4.8M
EBITDA
-$1.23M
$2.91M
$1.22M
$1.55M
$604K
$4.14M
$1.65M
-$691K
Basic earnings per share
-$0.10
-$0.02
-$0.03
$0.02
-$0.15
-$0.01
-$0.05
-$0.08
Diluted earnings per share
-$0.10
-$0.02
-$0.03
$0.02
-$0.15
-$0.01
-$0.05
-$0.08
Recent news
Company coverage with links to the original publishers.
Pomerantz LLP is investigating potential securities fraud claims against AirSculpt Technologies following a significant stock price decline of 45.11% on August 10, 2026, after the company reported lower-than-expected quarterly revenue of $42.9 million, down from $44.0 million year-over-year.
Pomerantz LLP has launched investigations into potential securities fraud and unlawful business practices at Securitize Corp., Fluence Energy, Inc., and AirSculpt Technologies, Inc. The law firm is seeking investors who suffered losses to join class action lawsuits against these companies.
Pomerantz LLP is investigating AirSculpt Technologies for potential securities fraud following the company's announcement of declining quarterly revenue ($42.9M vs $44.0M year-over-year) on August 10, 2026. The news triggered a significant stock price decline of 45.11%, falling from $5.01 to $2.75 per share.
AirSculpt Technologies appointed Mike Doyle as Non-Executive Chairman of its Board of Directors. Doyle brings over 30 years of leadership experience in multi-center healthcare and has previously led Surgery Partners and founded MD Healthcare Partners.
AirSculpt Technologies reported Q2 2025 financial results with declining case volume and revenue, but narrowed year-over-year revenue decline and reduced net loss. The company is piloting new offerings and remains confident in its growth strategy.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Aug 25, 2022
$0.41
Sep 14, 2022
special
Stock splits
Historical share-structure events and their execution dates.